Authors
Latest:
Unmet Needs for Managing CRS and ICANS Due to CAR T-Cell TherapyNicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.
Latest:
Exploring How to Get the Best Response in Frontline Multiple MyelomaCaitlin Costello, MD, discusses choosing the optimal first-line therapy for patients with multiple myeloma.
Latest:
Future Treatment Landscape for R/R MM with CAR-TBinod Dhakal, MD, explores how CAR-T therapy may impact the future treatment landscape for R/R MM, including current unmet needs and clinical pearls for community oncologists treating patients with R/R MM.
Latest:
Schroeder on the Evolving Ovarian Cancer Treatment LandscapeEric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.
Latest:
Treating Asymptomatic Patients With Polycythemia VeraJerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Latest:
Discussing Modakafusp Alfa as a Potential Treatment in RRMMDan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.
Latest:
MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Novel Treatment Approaches in Relapsed/Refractory Mantle Cell LymphomaManagement of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.
Latest:
Metastatic Breast Cancer Awareness Day: Assessing the Role of ADCsMuhammad Imam, MD, reviews the use of newer antibody-drug conjugates for patients with metastatic breast cancer across subtypes.
Latest:
Roundtable Discussion: Participants Explore Molecular Testing in the Lung Cancer SettingA 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.
Latest:
Safety of TKIs in Treatment of Differentiated Thyroid CancerWarren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Latest:
Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDSAmer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.
Latest:
Patient Case: 67-Year Old Female With Advanced SCLCFederico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.
Latest:
Next Steps in Anal Carcinoma ResearchCharles J. Schneider, MD, FACP, discusses some of the ongoing research examining patients with anal cell carcinoma.
Latest:
Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLCJorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.
Latest:
World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and TreatmentLynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.
Latest:
Closing Thoughts on Recent Data in GI CancerRohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ASCO Annual Meeting.
Latest:
Advice for Community Oncologists Treating Metastatic Castration-Resistant Prostate CancerDr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.
Latest:
Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCCManojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.
Latest:
Unmet Needs in R/R DLBCLDr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.
Latest:
Selecting Treatment for Late-Stage SCLCAfshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.
Latest:
Molecular Characteristics Determine Subtypes of Small Cell Lung CancerQian Wang, MD, MPH, discusses the progress of research into the molecular pathways responsible for developing small cell lung cancer.
Latest:
Examining Molecular Targets in SarcomaMark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.
Latest:
Examining Pelabresib for Patients With MyelofibrosisJoseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.
Latest:
Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin CancersNew and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.
Latest:
ctDNA Is Improving Oncology Care and Should Be Part of the Standard of CareMany oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.
Latest:
Sequencing Therapy With Novel Agents in Metastatic CholangiocarcinomaClinical pearls regarding molecular testing and treatment selection in metastatic cholangiocarcinoma.
Latest:
Phase 3 Study Demonstrates Intracranial Response in ALK+ NSCLCBenjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
